Patient-Derived Bladder Cancer Xenografts

  • Carina BernardoEmail author
  • Lúcio Lara Santos
Part of the Methods in Molecular Biology book series (MIMB, volume 1655)


Patient-derived xenograft (PDX ) tumors are models developed by direct transplant of human tumors into immune-compromised hosts such as nude mice. These models retain the histological and genetic characteristics of the primary tumor and are considered a valuable platform for translational cancer research. This chapter describes the methodology to establish and propagate bladder cancer PDX model.

Key words

Bladder cancer Xenograft Animal models Tumorgraft In vivo Drug testing 


  1. 1.
    Hidalgo M, Amant F, Biankin AV et al (2014) Patient-derived Xenograft models: an emerging platform for translational cancer research. Cancer Discov 4:998–1013. doi: 10.1158/2159-8290.CD-14-0001 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Tentler JJ, Tan AC, Weekes CD et al (2012) Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9:338–350. doi: 10.1038/nrclinonc.2012.61 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Voskoglou-nomikos T, Pater JL, Seymour L (2003) Clinical predictive value of the in vitro cell line, human Xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9:4227–4239PubMedGoogle Scholar
  4. 4.
    Cobb LM (1973) The behaviour of carcinoma of the large bowel in man following transplantation into immune deprived mice. Br J Cancer 28:400–411CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Houghton JA, Houghton PJ, Green AA (1982) Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice. Cancer Res 42:535–539PubMedGoogle Scholar
  6. 6.
    Fiebig HH, Schuchhardt C, Henss H et al (1984) Comparison of tumor response in nude mice and in the patients. Behring Inst Mitt:343–352Google Scholar
  7. 7.
    Hidalgo M, Bruckheimer E, Rajeshkumar NV et al (2011) A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 10:1311–1316. doi: 10.1158/1535-7163.MCT-11-0233 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Fichtner I, Slisow W, Gill J et al (2004) Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 40:298–307. doi: 10.1016/j.ejca.2003.10.011 CrossRefPubMedGoogle Scholar
  9. 9.
    Merk J, Rolff J, Becker M et al (2009) Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg 36:454–459. doi: 10.1016/j.ejcts.2009.03.054 CrossRefPubMedGoogle Scholar
  10. 10.
    Whittle JR, Lewis MT, Lindeman GJ, Visvader JE (2015) Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res 17:17. doi: 10.1186/s13058-015-0523-1 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Mattie M, Christensen A, Chang MS et al (2013) Molecular characterization of patient-derived human pancreatic tumor Xenograft models for preclinical and translational development of cancer therapeutics 1,2. Neoplasia 15:1138–1150. doi: 10.1593/neo.13922 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Park B, Jeong BC, Choi Y-LL et al (2013) Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue. Cancer Sci 104:1–8. doi: 10.1111/cas.12123 CrossRefGoogle Scholar
  13. 13.
    Bernardo C, Costa C, Amaro T et al (2014) Patient-derived sialyl-Tn-positive invasive bladder cancer xenografts in nude mice: an exploratory model study. Anticancer Res 34:735–744PubMedGoogle Scholar
  14. 14.
    McCue PA, Gomella LG, Veltri RW et al (1996) Development of secondary structure, growth characteristics and cytogenetic analysis of human transitional cell carcinoma xenografts in scid/scid mice. J Urol 155:1128–1132CrossRefPubMedGoogle Scholar
  15. 15.
    Abe T, Tada M, Shinohara N et al (2006) Establishment and characterization of human urothelial cancer xenografts in severe combined immunodeficient mice. Int J Urol 13:47–57. doi: 10.1111/j.1442-2042.2006.01220.x CrossRefPubMedGoogle Scholar
  16. 16.
    Pan C, Zhang H, Tepper CG et al (2015) Development and characterization of bladder cancer patient-derived Xenografts for molecularly guided targeted therapy. PLoS One 10:e0134346. doi: 10.1371/journal.pone.0134346 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Jäger W, Xue H, Hayashi T et al (2015) Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget 6:21522–21532. doi: 10.18632/oncotarget.3974 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Bernardo C, Costa C, Sousa N et al (2015) Patient-derived bladder cancer xenografts: a systematic review. Transl Res 166:324–331. doi: 10.1016/j.trsl.2015.02.001 CrossRefPubMedGoogle Scholar
  19. 19.
    Workman P, Aboagye EO, Balkwill F et al (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102:1555–1577. doi: 10.1038/sj.bjc.6605642 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Rubio-Viqueira B, Jimeno A, Cusatis G et al (2006) An platform for translational drug development in pancreatic cancer. Clin Cancer Res 12:4652–4661. doi: 10.1158/1078-0432.CCR-06-0113 CrossRefPubMedGoogle Scholar
  21. 21.
    Choi YY, Lee JE, Kim H et al (2016) Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci Rep 6:22172. doi: 10.1038/srep22172 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Calles A, Rubio-Viqueira B, Hidalgo M (2013) Primary human non-small cell lung unit and pancreatic tumorgraft models-utility and applications in drug discovery and tumor biology. Curr Protoc Pharmacol:1–21. doi: 10.1002/0471141755.ph1426s61

Copyright information

© Springer Science+Business Media LLC 2018

Authors and Affiliations

  1. 1.Experimental Pathology and Therapeutics Group—Research CenterPortuguese Oncology Institute—Porto (IPO-Porto)PortoPortugal
  2. 2.Institute for Biomedicine (IBiMED)University of AveiroPortoPortugal
  3. 3.Department of Surgical OncologyPortuguese Oncology Institute—Porto (IPO-Porto)PortoPortugal

Personalised recommendations